Sekhri Arunabh, Liu Delong, Rasul Muhammad, Ahmed Nasir, Ahmed Tauseef, Seiter Karen
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Leuk Res. 2009 Sep;33(9):1291-3. doi: 10.1016/j.leukres.2009.03.010. Epub 2009 Apr 3.
Allogeneic stem cell transplantation is considered to be a curative treatment modality in patients with chronic myelogenous leukemia. However patients are at risk for relapse years after transplantation. Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respectively. These patients emphasize the need for long term follow-up of such patients.